Pfizer-BioNTech Omicron-Adapted COVID-19 Vaccine Candidates Elicit Strong Immune Response
Pfizer and BioNTech announced positive findings from a study evaluating 2 Omicron-adapted COVID-19 vaccine candidates. The phase 2/3 trial assessed the safety, tolerability, and immunogenicity of a booster (fourth) dose of an Omicron-adapted monovalent vaccine…